SPG15 is caused by mutations in the ZFYVE26 gene. It is a progressive autosomal recessive disease, which means that both parents have passed on a mutation to defect the gene. ZFYVE26 encodes the FYVE domain-containing protein ZFYVE26/SPASTIZIN, which is associated with the adaptor protein 5 (AP5) complex. Spastizin is important in a process called autophagy, in which worn-out cell parts and unneeded proteins are recycled within cells. Specifically, spastizin is involved in the formation and maturation of sacs called autophagosomes (or autophagic vacuoles). Autophagosomes surround materials that need to be recycled. The autophagosome then attaches (fuses) to a cell structure called a lysosome, which breaks down and recycles the materials.
How common is Spastic Paraplegia Type 15?
The worldwide frequency of SPG15 has not been established. It is estimated that autosomal recessive hereditary spastic paraplegias occur in approximately 1 in 50,000 births. SPG15 has been reported to account for 3 to 15% of all cases of autosomal recessive hereditary spastic paraplegias.
Unfortunately, there is no cure for SPG15 at present. There is only symptom management available for example treating spasticity with medication, botox or even surgery for lengthening tight muscles.
If Juvenille Parkinsons is a symptom therefore it can be treated sometimes with a shorterm medication such as levodopa however once this has built up in the system it becomes less effective.
Exercise and physio is also a key to keeping muscles stronger before they atrophy as at this stage it becomes more difficult to gain muscle strength again.